• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Eleven Therapeutics, Novo Nordisk Reveal Nucleic Acid Therapy Collaboration


Companies aim to discover novel molecules that promote precise delivery of nucleic acid.

Lipid nanoparticle mRNA vaccine. Image Credit: Adobe Stock Images/Dr_Microbe

Image Credit: Adobe Stock Images/Dr_Microbe

Eleven Therapeutics, a biotechnology company focusing on developing RNA therapeutics through the combination of chemistry and artificial intelligence, has officially announced a research collaboration with Novo Nordisk. According to the biotech, the companies intend to leverage Eleven’s DELiveri™ platform to discover novel molecules that promote precise delivery of nucleic acid.

"Our research collaboration with Eleven Therapeutics builds on Novo Nordisk's commitment to advancing precision medicine and opens up the opportunity to learn from one another as we explore novel cell-specific targeting strategies,” said Uli Stilz, head, bio innovation hub, Novo Nordisk, in a press release. “With the combination of our joint team's expertise and using Eleven's DELiveri™ platform, we can potentially unlock transformative treatments for people living with cardiometabolic diseases."

Reference: Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics. PR Newswire. July 17, 2023. Accessed July 17, 2023. https://www.prnewswire.com/news-releases/eleven-therapeutics-announces-research-collaboration-with-novo-nordisk-to-discover-cell-specific-carriers-of-nucleic-acid-therapeutics-301878265.html

Related Videos
Related Content